pharmaceutical investing Ironwood and Alnylam Enter US GI Disease Education and Promotional Agreement
pharmaceutical investing Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO (patisiran), for the Treatment of ATTR Amyloidosis
Kobo Resources Intersects 21.5 m at 1.14 g/t Au and 20.0 m at 1.41 g/t Au at the Jagger Zone and Files FY 2025 Financial Results
Freegold Achieves over 90% Gold Recovery Using BIOX® and greater than 92% Gold Recovery using POX - Additional Metallurgical Work Remains Ongoing
Silver Crown Royalties Executes LOI with Kuya Silver for a Silver Royalty on the Bethania Silver Project
